Capitalization 5.29M P/E ratio 2024 *
-0.38x
P/E ratio 2025 * -4.16x
Enterprise value 4.2M EV / Sales 2024 *
0.13x
EV / Sales 2025 * 0.11x
Free-Float
71.71%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.67%
1 week-9.57%
Current month+15.81%
1 month+15.48%
3 months-37.35%
6 months-33.33%
Current year-62.45%
More quotes
1 week
1.00
Extreme 1
1.07
1 month
0.82
Extreme 0.8225
1.20
Current year
0.61
Extreme 0.61
3.90
1 year
0.61
Extreme 0.61
12.75
3 years
0.61
Extreme 0.61
292.60
5 years
0.61
Extreme 0.61
292.60
10 years
0.61
Extreme 0.61
292.60
More quotes
Insider TitleAgeSince
Chief Executive Officer 68 15-02-28
Director of Finance/CFO 40 22-10-23
Director of Finance/CFO - 19-07-31
Insider TitleAgeSince
Chief Executive Officer 68 15-02-28
Director/Board Member 66 21-11-01
Director/Board Member 67 15-03-02
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+1.67%-9.57%-91.84% - 5.21M
-2.10%-5.05%+87.21%+252.19% 791B
-2.16%-1.81%+64.07%+216.13% 595B
+2.58%-0.19%-8.65%-9.03% 367B
+1.24%+0.02%+15.75%+62.39% 315B
+1.77%+0.54%+23.07%+49.09% 306B
+0.07%-0.18%0.00%-21.25% 247B
+0.20%-0.25%+13.30%+44.03% 244B
+0.08%-2.83%+6.01%+13.82% 218B
+0.71%-0.02%+42.56%+35.48% 179B
Average -0.12%-1.66%+15.15%+71.43% 326.15B
Weighted average by Cap. -0.56%-1.87%+39.27%+114.74%
See all sector performances
Ratios2024 *2025 *
Net sales 39.59M 49.71M
Net income -20.26M -3.87M
Net Debt - -
More financial data * Estimated data
Logo Biofrontera Inc.
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Employees
84
More about the company
Date Price Change Volume
24-07-24 1.040 $ +1.67% 37,217
24-07-23 1.023 $ +1.28% 74,795
24-07-22 1.010 $ 0.00% 10,281
24-07-19 1.010 $ -1.94% 29,651
24-07-18 1.030 $ -10.43% 116,219

Delayed Quote Nasdaq, July 24, 2024 at 03:56 pm EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.040USD
Average target price
16.00USD
Spread / Average Target
+1,438.46%
Consensus